Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes, Am J Nephrol, vol.46, pp.213-221, 2017. ,
, FIGURE 2: RAASi use and HK treatment at HK1/HK2 in the 12-month observational period in the subgroups of patients with (A) HFrEF (n ¼ 333) or (B) DN (n ¼ 376)
New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors, Cardiovasc Drugs Ther, vol.32, pp.99-119, 2018. ,
, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of chronic kidney disease, Kidney Int Suppl, vol.3, pp.1-150, 2013.
, Chronic Kidney Disease in Adults: Assessment and Management. Clinical guideline (CG182, p.15, 2018.
, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, vol.316, pp.1429-1435, 1987.
The frequency of hyperkalemia and its significance in chronic kidney disease, Arch Intern Med, vol.169, pp.1156-1162, 2009. ,
Management of hyperkalemia: an update for the internist, Am J Med, vol.128, pp.1281-1287, 2015. ,
Long-term potassium monitoring and dynamics in heart failure and risk of mortality, Circulation, vol.137, pp.1320-1330, 2018. ,
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial, Eur Heart J, vol.32, pp.820-828, 2011. ,
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors, N Engl J Med, vol.372, pp.211-221, 2015. ,
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 2019. ,